Blockchain Registration Transaction Record

Helus Pharma Applauds White House Push for Psychedelic Treatments

Helus Pharma welcomes White House Executive Order to accelerate psychedelic treatment research & access. Its Phase 3 depression drug HLP003 has FDA Breakthrough Therapy designation.

This news matters because it signals a major shift in federal policy that could dramatically accelerate the availability of new mental health treatments. The White House Executive Order represents a significant governmental endorsement of psychedelic-assisted therapies, potentially streamlining the FDA review process and increasing funding for research. For the millions suffering from treatment-resistant depression and anxiety, this could mean faster access to potentially life-changing medications like Helus Pharma's HLP003. The company's Breakthrough Therapy designation already indicates the therapy's promise, and this executive action could help bring it to patients sooner. Furthermore, it validates the entire emerging psychedelic medicine sector, potentially attracting more investment and research into novel treatments for the global mental health crisis.